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2. Abstract 
Importance Acetaminophen (paracetamol) is used by a large proportion of pregnant women. 
Research suggests that acetaminophen use in pregnancy is associated with abnormal 
neurodevelopment. However, it is possible that this association might be confounded by 
unmeasured behavioural factors linked to acetaminophen use.  
Objective To examine associations between (1) maternal prenatal acetaminophen use, (2) 
maternal postnatal acetaminophen use, (3) partner’s acetaminophen use and offspring 
behavioral problems. 
Design Avon Longitudinal Study of Parents and Children (ALSPAC). Participants enrolled 
between 1991 and 1992 in Bristol, UK. 
Setting Prospective birth cohort of parents and children. 
Participants We studied 7796 mothers with their children and partners from ALSPAC 
Exposures Acetaminophen use was assessed by questionnaire completion at 18 and 32 weeks 
of pregnancy and when the child was 61 months old.  
Main outcomes and measures Maternal reports of behavioral problems using the Strengths 
and Difficulties Questionnaire (SDQ) when the children were 7 years of age. We estimated 
risk ratios for behavioral problems in children after prenatal, postnatal and partner’s exposure 
to acetaminophen and mutually adjusted each association.  
Results Maternal prenatal acetaminophen use at 18 and 32 weeks was associated with higher 
odds of having conduct problems (risk ratio: 1.42 (95% CI: 1.25 - 1.62)) and hyperactivity 
symptoms (risk ratio: 1.31 (95% CI: 1.16 - 1.49)), while maternal acetaminophen use at 32 
weeks was also associated with higher odds of having emotional symptoms (risk ratio: 1.29 
(95% CI: 1.09 - 1.53)) and total difficulties (risk ratio: 1.46 (95% CI: 1.21 - 1.77)). This was 
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not the case for maternal postnatal or partner’s acetaminophen use. The associations between 
maternal prenatal acetaminophen use and all the SDQ domains remained unchanged even 
when adjusting for maternal postnatal or partner’s acetaminophen use.   
Conclusions and Relevance Children exposed to acetaminophen prenatally are at increased 
risk of multiple behavioral difficulties and the associations do not appear to be explained by 
unmeasured behavioral/social factors linked to acetaminophen use insofar as they are not 
observed for postnatal or partner’s acetaminophen use. Although these results could have 
implications for public health advice, further studies are required to replicate the findings and 
to understand mechanisms.  
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3. Main Text 
Introduction 
Acetaminophen (paracetamol) is one of the most common pain-relieving medications and is 
considered generally safe for use during all stages of pregnancy making it the first choice 
pain and fever medication for pregnant women. Given the large number of pregnant women 
using the drug (>50% in US,1 50 - 60% in the EU2), even a small increase in risk of adverse 
outcomes in the offspring can have important implications for public health.  
Animal studies suggest that acetaminophen use in pregnancy can have important implications 
for neurodevelopment; acetaminophen administration during neonatal brain development in 
mice affected cognitive function and disrupted levels of BDNF (Brain-Derived Neurotrophic 
Factor) in the brain.3 The mechanism could be through disrupted endocrine function which is 
important for neurodevelopment.4 For example, acetaminophen use in pregnancy has been 
found to disrupt endocrine testicular function in male embryos with long-term acetaminophen 
use linked to an increase in risk of cryptorchidism.5 
Acetaminophen use during pregnancy is associated with higher risk of hyperkinetic disorders 
and ADHD-like behaviors. This has been observed in a very large sample of children and 
their mothers from the Danish National Birth Cohort.6 Similar results were also reported in a 
cohort of children and their mothers from New Zealand.7 In addition, a sibling-controlled 
cohort study that partially accounted for familial confounding found that long-term 
acetaminophen use during pregnancy was associated with adverse developmental outcomes at 
3 years of age.8  
Although a large number of potential confounders were accounted for in the previous studies, 
there is still the possibility of unmeasured confounding being present. Maternal behaviors 
during pregnancy, including acetaminophen use, can be associated with multiple maternal 
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factors including socio-economic ones as well as disease and health outcomes, such as 
behavioral difficulties in the offspring.9 One mechanism behind the association between 
maternally-influenced prenatal factors and offspring outcome is genetic confounding, 
whereby a risk factor and a disease have shared genetic influences. For example, genetic 
confounding has been shown to be present in the association between smoking during 
pregnancy, another prenatal risk factor, and ADHD10 and behavioral problems.11   
Study designs that take into account unmeasured and familial confounding are required to 
inform public health advice on acetaminophen use in pregnancy.12 Although they have 
already been applied to suggest that the association between prenatal acetaminophen 
exposure and asthma is unlikely to be due to unmeasured behavioral factors,13 they have not 
been employed to investigate the effect of prenatal acetaminophen on offspring behavioral 
difficulties.  The design of these studies includes comparisons between maternal prenatal 
exposures and maternal postnatal exposures as well as partner’s exposures during pregnancy. 
If an intrauterine effect of acetaminophen exposure on offspring behavior is present, one 
would expect association with maternal prenatal exposure but not with maternal postnatal 
exposure or partner’s exposure because the latter two exposures cannot have a direct 
biological effect on the fetus.14 For example, effects of maternal smoking in pregnancy on 
birth weight14 were stronger than that of partner’s smoking in the Avon Longitudinal Study of 
Parents and Children (ALSPAC) in line with other evidence suggesting a causal intrauterine 
mechanism. However, partner’s smoking had a similar effect to maternal smoking on 
offspring body fat mass.15  
 In this study, we assessed associations between (1) maternal prenatal acetaminophen use, (2) 
maternal postnatal acetaminophen use, (3) partner’s acetaminophen use and behavioral 
problems in offspring at seven years of age in the ALSPAC population cohort.  
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Methods 
Study population 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective birth 
cohort which recruited pregnant women with expected delivery dates between April 1991 and 
December 1992 from Bristol UK. 14 541 pregnant women were initially enrolled with 14 062 
children born. Detailed information on health and development of children and their parents 
were collected from regular clinic visits and completion of questionnaires. A detailed 
description of the cohort has been published previously.16,17 The study website contains 
details of all the data that is available through a fully searchable data dictionary: 
http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/. Ethical approval was 
obtained from the ALSPAC Law and Ethics Committee and the Local Ethics Committees.   
Acetaminophen use by the mother and her partner 
Mothers were asked at 18 and 32 weeks of pregnancy if they had used acetaminophen in the 
previous three months. The same question was asked again of the mother and her partner 
when the child was 61 months old. They were also asked if they suffered from muscle and 
joint problems, infections (including cold/flu, urinary or other infections), migraine or 
headaches at the same periods. However, they were not asked detailed questions on dose, 
duration and indications of use.  
Outcomes 
We assessed children’s behavioral problems using the Strengths and Difficulties 
Questionnaire (SDQ), a behavioral screening questionnaire (age range 4–16 years) which 
includes questions on five domains: emotional symptoms, conduct problems, hyperactivity 
symptoms, peer relationship problems and prosocial behaviors ranging from 0 to 10 each.18  
A total difficulties score can be obtained by summing the following subscales: emotional 
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symptoms, conduct problems, hyperactivity symptoms and peer relationship problems (not 
including prosocial behavior for which a higher score indicates less behavioral problems). 
SDQ total difficulties score ranges from 0 to 40 (www.sdqinfo.com).  Mother reports on their 
children's behavioral problems were obtained at 7 years of age. Cut-offs were used to 
dichotomize each of the five SDQ subscales as well as total difficulties score according to 
previous studies.18  
Confounding factors 
We repeated all our analyses including potential confounding factors: maternal age at birth, 
parity, socioeconomic status, smoking and alcohol consumption during pregnancy, pre-
pregnancy BMI, maternal self-reported psychiatric illness and possible indications for 
acetaminophen use. Mothers were asked to report whether they smoked or consumed alcohol 
during pregnancy by completing a questionnaire at 32 weeks of pregnancy. At the same time 
point they were also asked if they suffered from muscle and joint problems, infections 
(including cold/flu, urinary or other infections), migraine or headaches in the previous 3 
months. We decided to include the previous factors in the model as they are the most 
common indications for acetaminophen use.  
Genetic confounders 
Composite scores of molecular genetic risk factors for ADHD (polygenic risk scores) were 
calculated for 8 340 ALSPAC mothers using available genotype data (details on the quality 
control procedure have been published previously19) according to the method described by 
the International Schizophrenia Consortium (ISC).20 Polygenic risk scores were computed 
using “risk alleles” based on the results of an independent case-control UK/Irish ADHD 
genome-wide association study (GWAS) (discovery sample). Quality control procedures, 
ascertainment of these samples and GWAS results have been described in detail previously.21  
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In line with previous studies,22,23 a threshold of p<0.5 was used to select alleles more 
common in cases than controls from the discovery sample (SNPs in relative linkage 
equilibrium in the discovery sample GWAS were first selected). These identified SNPs were 
used to calculate a polygenic score for each individual in ALSPAC, corresponding to the 
mean number of score alleles (weighted by the logarithm of the odds ratio) across the set of 
SNPs. Analysis was performed using PLINK.24 Logistic regression was employed to test if 
maternal ADHD polygenic risk scores were associated with maternal prenatal and postnatal 
acetaminophen use. Paternal genotype data were unavailable. 
Statistical analyses 
We used generalized linear models with a log-link function and a Poisson distribution to 
estimate risk ratios and 95% confidence intervals (CIs) for prenatal and postnatal 
acetaminophen use and the dichotomized SDQ domains. As a sensitivity analysis, SDQ 
domains were also analysed as continuous outcomes after logarithmic transformation.  
To address potential confounding by unmeasured genetic and non-genetic confounders, we 
compared maternal prenatal acetaminophen use to maternal postnatal acetaminophen use as 
exposures for each outcome. Then, we mutually adjusted each association and compared the 
effect of the adjustment. The same analysis with mutual adjustment was carried out to 
compare maternal prenatal acetaminophen use to partner’s postnatal acetaminophen use as 
exposures.  
All previous analyses were repeated with the inclusion of potential confounders described 
above. All information on confounding factors was obtained by questionnaire completion 
from the mother and her partner.  
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Results 
Acetaminophen use was reported by 4 415 mothers (53%) at 18 weeks of pregnancy and by  
3 381 mothers (42%) at 32 weeks. 6 916 mothers (89%) and 3 454 partners (84%) used 
acetaminophen postnatally. 5% of children had behavioral problems as indicated by the total 
difficulties score of the SDQ (eTable 1 in Supplement for details on the number of children 
with behavioral problems). The mean age of children at completion of the SDQ questionnaire 
by the parents were 6 years and 7 months (SD 1.3 months). Other characteristics of mothers 
reporting acetaminophen use in ALSPAC and their children are described in Table 1. All of 
them were included in the adjusted analysis reported in eTables 2-5 in Supplement.  
Maternal prenatal acetaminophen use at 18 weeks was associated with higher odds of 
offspring conduct problems (risk ratio: 1.20 (95% CI: 1.06 - 1.37)) and hyperactivity 
symptoms (risk ratio: 1.23 (95% CI: 1.08 - 1.39)), while maternal acetaminophen use at 32 
weeks was associated with higher odds of offspring having emotional symptoms (risk ratio: 
1.29 (95% CI: 1.09 - 1.53)), conduct problems (risk ratio: 1.42 (95% CI: 1.25 - 1.62)), 
hyperactivity symptoms (risk ratio: 1.31 (95% CI: 1.16 - 1.49)) and total difficulties (risk 
ratio: 1.46 (95% CI: 1.21 - 1.77)), as assessed by the SDQ (Table 2). This was not the case 
for maternal postnatal acetaminophen use or partner’s acetaminophen use, which were not 
associated with any of the SDQ domains (Table 3). Inclusion of covariates did not change the 
risk ratios, although confidence intervals were wider due to the reduced sample size when 
including covariates (eTables 2 and 3 in Supplement).  
After mutual adjustment of maternal prenatal and maternal postnatal acetaminophen use, the 
associations between maternal prenatal acetaminophen use and all the SDQ domains 
remained unchanged while the associations for maternal postnatal acetaminophen use were 
attenuated (Table 4).  
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When adjusting maternal prenatal acetaminophen use for partner’s acetaminophen use, the 
effect was unchanged despite the smaller sample size in this analysis (Table 5).  
All analyses were repeated with potential confounders including genetic ones and are 
presented in eTables 2-5 in Supplement. In linear regression models, results were similar 
(eTables 6-9 in Supplement).  
We could not find evidence of robust association between maternal ADHD polygenic risk 
scores and maternal prenatal acetaminophen at 18 weeks (beta coefficient per SD of 
polygenic risk score: -0.002 (95% CI: (-0.01 to 0.009), p=0.8), 32 weeks (beta coefficient per 
SD of polygenic risk score: -0.004 (95% CI: (-0.02 to 0.007), p=0.5) or with postnatal 
acetaminophen use (beta coefficient per SD of polygenic risk score: -0.008 (95% CI: (-0.01 to 
0.0009), p=0.06).  
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Discussion 
In this study, we have demonstrated that children exposed prenatally to acetaminophen in the 
second and third trimesters are at increased risk of multiple behavioral difficulties including 
hyperactivity, and conduct problems. Prenatal exposure at 32 weeks was also associated with 
emotional problems. The associations did not change when maternal postnatal or partner’s 
acetaminophen use were included in the model. Similar to the Danish National Registry 
observations6 the associations were also not confounded by maternal migraine, infections and 
other measured factors. In addition, there was no evidence of association between an index of 
ADHD genetic risk in the mothers and acetaminophen use in pregnancy. These findings when 
coupled with those from the previous discordant sibling design study8 suggest that the 
association between prenatal acetaminophen exposure on childhood behavioral problems 
does not appear to be explained by unmeasured familial factors linked to both acetaminophen 
use and childhood behavioral problems and that the findings are consistent with an 
intrauterine effect. Our results could have important implications for public health advice 
which currently considers acetaminophen safe to use during pregnancy.  
Our results suggest that the timing of acetaminophen use might be important. More 
specifically, we report stronger association between maternal acetaminophen use and 
multiple behavioral/emotional problem domains during the third trimester compared to the 
second in accordance with previous studies that have included multiple time points in 
pregnancy.8 Given that there is active brain development and growth during the third 
trimester, this finding could indicate that there are developmental time points when the brain 
is more sensitive to acetaminophen exposure.  
The mechanism through which adverse outcomes of acetaminophen on fetal 
neurodevelopment could be mediated are not well understood.12 One mechanism could be 
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through the endocrine-disrupting properties of acetaminophen. The disruption of the maternal 
hormonal milieu can impact on fetal brain development. It is well known that thyroid 
hormones, for example, are important for fetal brain development.4 It is also known that 
acetaminophen crosses the placenta25 and animal studies have shown that the fetus is capable 
of producing the toxic metabolites of acetaminophen.26 This highlights the need for further 
experimental research to identify potential causal mechanisms. Another possibility is that 
acetaminophen disrupts brain development through oxidative stress. Studies in humans 
suggest that long-term use of acetaminophen reduces serum antioxidants and disrupts 
oxidant-antioxidant balance.27 Increased amounts of oxidants in the fetus can then lead to 
neuronal death at critical points during development.28 
One strength of this study is the availability of prospective information on acetaminophen use 
during the second and third trimester of pregnancy and postnatally by the mother as well as 
by her partner. This enables us to use a nested quasi-experimental design whereby we assess 
the effect of acetaminophen use during pregnancy on offspring behavioral difficulties and 
compare it with maternal postnatal acetaminophen use and partner’s acetaminophen use 
which are likely associated with stable social and familial factors as prenatal maternal use but 
cannot have a biological effect on fetal brain development. This approach has been used 
previously in ALSPAC to suggest that the association between prenatal acetaminophen use 
and asthma in the offspring does not appear to be confounded by unmeasured behavioral 
factors.13 Our study also had the advantage of assessing the effect of acetaminophen at two 
different time points in fetal development.  
We were also able to adjust the associations for a large number of potential confounders as 
well as ADHD genetic risk scores in the mothers. The same genetic factors could be 
influencing behavioral problems as well as risky behaviors during pregnancy that would 
result in genetic confounding. This has been shown to contribute to the association between 
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maternal smoking during pregnancy and offspring ADHD.10 However, ADHD polygenic risk 
scores were not associated with maternal acetaminophen use during pregnancy in ALSPAC. 
Another advantage of our study was the use of the SDQ which is a validated and reliable 
screening instrument for behavioral problems in children.29 Finally, recall bias for 
acetaminophen use should not be present in this study because the questionnaire on 
acetaminophen use was administered several years before the SDQ.  
A limitation of this study is that there was no maternally-reported information on the 
indications for acetaminophen use. However, we were able to adjust for the most common 
reasons which include headaches, musculoskeletal problems and infections during pregnancy. 
While there is no evidence of a possible correlation between these health conditions during 
pregnancy and behavioral problems in the offspring, we cannot rule out the possibility of 
residual confounding or fetal effects on maternal health during pregnancy. We also did not 
have information on dosage or duration of acetaminophen use to test whether long-term or 
large doses of acetaminophen are more detrimental than casual use. However, only 0.1% 
reported acetaminophen use every day during the previous 3 months. Another concern could 
be that information on postnatal  acetaminophen use was only collected when the child was 5 
years old. However, irrespective of the timing, postnatal acetaminophen use for mother and 
partner cannot have a causal biological intra-uterine effect effect and it is a valid indicator of 
stable confounding factors shared within families Nonetheless, this will not be the case for 
confounding factors that have changed since the birth of the child. In addition, although the 
majority of partners (97%) considered themselves the biological father of their child and they 
were all living with the mothers at the time the questionnaire was completed, there were no 
genetic data on partners to confirm paternity. An additional limitation is that polygenic 
genetic risk scores for complex disorders explain only a small proportion of phenotype 
variance.30 However, there is no reason to believe that the genetic contribution to ADHD not 
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picked up by these scores would have a different association with acetaminophen use. 
Finally, measures of exposures and outcome involved maternal reports; thus, shared rater 
effects cannot be completely ruled out. However, mothers also reported on postnatal use of 
acetaminophen. 
 
Conclusions 
Children exposed to acetaminophen use prenatally are at increased risk of multiple behavioral 
difficulties. The associations were not observed for postnatal or partner’s acetaminophen use 
which indicates these might not be explained by unmeasured behavioral/social factors linked 
to acetaminophen use. Our findings suggest that the association between acetaminophen use 
during pregnancy and offspring behavioral problems in childhood may be due to an 
intrauterine mechanism. Further studies are required to elucidate mechanisms behind this 
association as well as test alternatives to a causal explanation. Given the widespread use of 
acetaminophen amongst pregnant women, this can have important implications on public 
health advice. However, the risk of not treating fever or pain during pregnancy should be 
carefully weighed against any potential harm to the offspring. 
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6. Tables 
Table 1. Characteristics of mothers reporting acetaminophen use in ALSPAC and their children 
Characteristic Maternal prenatal use 32 weeks (n, %) Maternal postnatal use (n, %) 
Maternal age at birth (years)   
 
Never  
(n = 4 681, 58%) 
Ever  
(n = 3 381, 42%) 
Never  
(n = 845, 11%) 
Ever  
(n = 6 916, 89%) 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
 29.2 (4.5) 29.1 (4.5) 29.7 (4.8) 29.1 (4.5) 
Gestational age (weeks)   
 
Never  
(n = 4 326, 58%) 
Ever  
(n = 3 071, 42%) 
Never  
(n = 794, 11%) 
Ever  
(n = 6 603, 89%) 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
 39. 5 (1.8) 39.6 (1.7) 39.5 (1.8) 39.5 (1.7) 
Birthweight (g)   
 
Never  
(n = 4 272, 58%) 
Ever  
(n = 3 038, 42%) 
Never  
(n = 785, 11%) 
Ever  
(n = 6 525, 89%) 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
 3 419.1 (531.4) 3 446.9 (526.1) 3 404.8 (549.8) 3 433.7 (526.8) 
Maternal pre-pregnancy BMI   
 
Never  
(n = 4 039, 59%) 
Ever 
 (n = 2 832, 41%) 
Never  
(n = 732, 11%) 
Ever  
(n = 6 139, 89%) 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
 22.6 (3.5) 23.3 (3.9) 22.9 (3.8) 22.9 (3.7) 
   
Socioeconomic status Never (n, %) Ever (n, %) Never (n, %) Ever (n, %) 
Low 609 (15.8) 429 (16.3) 142 (20.6) 2 431 (42) 
Intermediate 1 631 (42.4) 1 121 (42.6) 287 (41.7) 2 465 (42.6) 
High 1 608 (41.8) 1 082 (41.1) 259 (37.7) 896 (15.5) 
   
Maternal psychiatric illness Never (n, %) Ever (n, %) Never (n, %) Ever (n, %) 
No psychiatric illness 3 922 (93.3) 2 641 (89.8) 688 (91.4) 5 875 (91.9) 
Presence of psychiatric illness 283 (6.7) 300 (10.2) 65 (8.6) 518 (8.1) 
   
Maternal smoking during 
pregnancy Never (n, %) Ever (n, %) Never (n, %) Ever (n, %) 
Never smoker 3 582 (83.3) 2 398 (78.7) 626 (79.7) 5 354 (81.4) 
Ever smoker 720 (16.7) 650 (21.3) 159 (20.3) 1 370 (18.6) 
   
Maternal alcohol consumption 
during pregnancy Never (n, %) Ever (n, %) Never (n, %) Ever (n, %) 
No alcohol 1 992 (46.5) 1 217 (40.1) 358 (45.8) 2 851 (43.6) 
Ever alcohol 2 295 (53.5) 1 820 (59.9) 424 (54.2) 3 691 (56.4) 
 
Abbreviations: ALSPAC, Avon Longitudinal Study of Parents and Children; SD, Standard Deviation 
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Table 2. Risk ratios (RR) for SDQ behavioral problems domains and maternal acetaminophen use at 18 weeks 
and 32 weeks of pregnancy 
  Maternal prenatal use at 18 weeks Maternal prenatal use at 32 weeks 
  N = 8 317 N = 8 062 
Outcome RR (95% CIs) RR (95% CIs) 
SDQ total difficulties (scores >=17) 1.16 (0.97 - 1.40) 1.46 (1.21 - 1.77) 
Emotional symptoms (scores >=5) 1.11 (0.94 - 1.31) 1.29 (1.09 - 1.53) 
Conduct problems (scores >=4) 1.20 (1.06 - 1.37) 1.42 (1.25 - 1.62) 
Hyperactivity symptoms (scores >=7) 1.23 (1.08 - 1.39) 1.31 (1.16 - 1.49) 
Peer problems (scores >=4) 1.07 (0.91 - 1.25) 1.09 (0.92 - 1.28) 
Prosocial behavior (scores <=6) 1.00 (0.91 - 1.09) 1.04 (0.95 - 1.14) 
Abbreviations: SDQ, Strengths and Difficulties Questionnaire; RR, Risk Ratio; CIs, Confidence Intervals 
 
 
Table 3. Risk ratios (RR) for SDQ behavioral problems domains and maternal postnatal (61 months) and 
partner’s postnatal acetaminophen use (61 months)  
  Maternal postnatal use Partner’s postnatal use 
  N = 7 761 N = 4 095 
Outcome RR (95% CIs) RR (95% CIs) 
SDQ total difficulties (scores >=17) 1.29 (0.92 - 1.83) 1.09 (0.74 - 1.61) 
Emotional symptoms (scores >=5) 1.26 (0.94 - 1.71) 1.23 (0.87 - 1.74) 
Conduct problems (scores >=4) 1.10 (0.89 - 1.37) 1.38 (1.02 - 1.88) 
Hyperactivity symptoms (scores >=7) 1.10 (0.89 - 1.36) 1.27 (0.96 - 1.69) 
Peer problems (scores >=4) 1.05 (0.8 - 1.38) 0.91 (0.66 - 1.26) 
Prosocial behavior (scores <=6) 1.02 (0.88 - 1.19) 0.97 (0.82 - 1.16) 
Abbreviations: SDQ, Strengths and Difficulties Questionnaire; RR, Risk Ratio; CIs, Confidence Intervals 
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Table 4. Comparison of effects of maternal prenatal (18 and 32 weeks) and postnatal (61 months) 
acetaminophen use on SDQ behavioral problems domains after mutual adjustment  
 
  
Maternal prenatal 
use at 18 weeks 
adjusted for 
postnatal use 
Maternal prenatal 
use at 32 weeks 
adjusted for 
postnatal use 
Maternal postnatal 
use adjusted for 
prenatal use at 18 
weeks 
Maternal postnatal 
use adjusted for 
prenatal use at 32 
weeks 
  N = 7 535 N = 7 317 N = 7 535 N = 7 317 
Outcome RR (95% CIs) RR (95% CIs) RR (95% CIs) RR (95% CIs) 
SDQ total 
difficulties 
(scores >=17) 
1.12 (0.92 - 1.37) 1.47 (1.20 - 1.80) 1.23 (0.87 - 1.75) 1.14 (0.80 - 1.63) 
Emotional 
symptoms 
(scores >=5) 
1.06 (0.89 - 1.26) 1.24 (1.04 - 1.48) 1.22 (0.90 - 1.67) 1.14 (0.83 - 1.55) 
Conduct 
problems 
(scores >=4) 
1.18 (1.03 - 1.36) 1.40 (1.22 - 1.60) 1.05 (0.84 - 1.31) 0.98 (0.78 - 1.23) 
Hyperactivity 
symptoms 
(scores >=7) 
1.21 (1.06 - 1.38) 1.34 (1.17 - 1.53) 1.05 (0.84 - 1.31) 1.05 (0.84 - 1.32) 
Peer 
problems 
(scores >=4) 
1.05 (0.89 - 1.24) 1.08 (0.91 - 1.28) 1.00 (0.76 - 1.32) 0.98 (0.74 - 1.30) 
Prosocial 
behavior 
(scores <=6) 
0.99 (0.90 - 1.09) 1.03 (0.93 - 1.13) 1.03 (0.88 - 1.20) 1.04 (0.89 - 1.22) 
Abbreviations: SDQ, Strengths and Difficulties Questionnaire; RR, Risk Ratio; CIs, Confidence Intervals 
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Table 5. Comparison of effects of maternal prenatal (18 and 32 weeks) and partner’s postnatal (61 months) 
acetaminophen use on SDQ behavioral problems domains after mutual adjustment 
  
Maternal prenatal 
use at 18 weeks 
adjusted for 
partner's use 
Maternal prenatal 
use at 32 weeks 
adjusted for 
partner's use 
Partner's use 
adjusted for 
maternal prenatal 
use at 18 weeks  
Partner's use 
adjusted for 
maternal prenatal 
use at 32 weeks  
  N = 4 044 N = 3 951 N = 4 044 N = 3 951 
Outcome RR (95% CIs) RR (95% CIs) RR (95% CIs) RR (95% CIs) 
SDQ total 
difficulties 
(scores >=17) 
1.41 (1.06 -1.88) 1.85 (1.39 - 2.47) 1.05 (0.71 - 1.55) 1.15 (0.75 - 1.75) 
Emotional 
symptoms 
(scores >=5) 
1.04 (0.83 -1.32) 1.20 (0.94 - 1.52) 1.25 (0.88 - 1.77) 1.34 (0.92 - 1.95) 
Conduct 
problems 
(scores >=4) 
1.39 (1.14 -1.70) 1.53 (1.25 - 1.87) 1.36 (1.00 - 1.86) 1.38 (1.00 - 1.89) 
Hyperactivity 
symptoms 
(scores >=7) 
1.27 (1.05 -1.53) 1.43 (1.18 - 1.73) 1.26 (0.95 - 1.68) 1.28 (0.95 - 1.71) 
Peer 
problems 
(scores >=4) 
1.22 (0.96 -1.57) 1.21 (0.95 - 1.56) 0.89 (0.65 - 1.24) 0.97 (0.69 - 1.36) 
Prosocial 
behavior 
(scores <=6) 
1.00 (0.88 - 1.14) 1.03 (0.91 - 1.17) 0.96 (0.81 - 1.14) 0.97 (0.81 - 1.15) 
Abbreviations: SDQ, Strengths and Difficulties Questionnaire; RR, Risk Ratio; CIs, Confidence Intervals 
 
